Atlas Trials

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

Clinical trial NCT07646613 · RECRUITING

Trial details

NCT number
NCT07646613
Sponsor
Aspeya, Inc.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Migraine
Start date
2026-05-19
Primary completion
2026-12-01
Enrollment
108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.